[HTML][HTML] Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population

…, K Nouso, A Morishita, A Tsutsui, T Nagano… - European Journal of …, 2023 - Elsevier
Background and aims Atezolizumab plus bevacizumab and lenvatinib have not been
compared in a randomised controlled trial. We conducted a retrospective multi-centre study to …

Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real‐world conditions—Multicenter analysis

…, H Toyoda, K Nouso, A Tsutsui, T Nagano… - Cancer …, 2019 - Wiley Online Library
Background/aim We assessed suitable factors indicating newly developed lenvatinib (LEN)
treatment for unresectable hepatocellular carcinoma (u‐HCC) by investigating real‐world …

Therapeutic efficacy of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma in patients with child‐Pugh class a or B liver function in …

…, K Nouso, A Morishita, A Tsutsui, T Nagano… - Hepatology …, 2022 - Wiley Online Library
Background/Aim Atezolizumab plus bevacizumab (Atez/Bev) treatment is recommended for
unresechepatocellular carcinoma (u‐HCC) patients classified as Child‐Pugh A (CP‐A). This …

Cytokine profile in the liver of primary biliary cirrhosis

T Nagano, K Yamamoto, S Matsumoto… - Journal of clinical …, 1999 - Springer
We characterized the cytokine profile in the liver of patients with primary biliary cirrhosis (PBC).
Total RNA was extracted from the biopsy specimens of 9 patients with early-stage PBC, …

Prognostic impact of C-reactive protein and alpha-fetoprotein in immunotherapy score in hepatocellular carcinoma patients treated with atezolizumab plus …

…, K Nouso, A Morishita, A Tsutsui, T Nagano… - Hepatology …, 2022 - Springer
Aim This study aimed to investigate the utility of C-reactive protein (CRP) and alpha-fetoprotein
(AFP) in immunotherapy (CRAFITY) score in hepatocellular carcinoma (HCC) patients …

Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma: Early clinical experience

…, K Nouso, A Morishita, A Tsutsui, T Nagano… - Cancer …, 2022 - Wiley Online Library
Background Although atezolizumab plus bevacizumab (Atez/bev) treatment has been
developed for unresectable hepatocellular carcinoma (u‐HCC), changes in hepatic function …

Important clinical factors in sequential therapy including lenvatinib against unresectable hepatocellular carcinoma

…, T Tada, H Toyoda, K Nouso, A Tsutsui, T Nagano… - Oncology, 2019 - karger.com
Background/Aim: We evaluated clinical factors related to improved prognosis of unresectable
hepatocellular carcinoma patients (u-HCC), who were treated with tyrosine kinase inhibitor …

Neutrophil–lymphocyte ratio predicts early outcomes in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab: a …

…, A Morishita, A Tsutsui, T Nagano… - European Journal of …, 2022 - journals.lww.com
Objective: To investigate whether neutrophil-to-lymphocyte ratio (NLR) can predict outcomes
in patients with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab …

Does first‐line treatment have prognostic impact for unresectable HCC?—Atezolizumab plus bevacizumab versus lenvatinib

…, K Nouso, A Morishita, A Tsutsui, T Nagano… - Cancer …, 2023 - Wiley Online Library
Background/Aim A comparison of therapeutic efficacy between atezolizumab plus
bevacizumab (Atez/Bev) and lenvatinib treatment given as first‐line therapy for unresectable …

Lenvatinib versus Sorafenib in first‐line treatment of unresectable hepatocellular carcinoma: an inverse probability of treatment weighting analysis

…, M Imai, K Takaguchi, A Tsutsui, T Nagano… - Liver …, 2021 - Wiley Online Library
Purpose Data from common clinical practice were used to generate balanced cohorts of
patients receiving either sorafenib or lenvatinib, for unresectable hepatocellular carcinoma, with …